Dr. Reddy's Biosimilar Ambition
Executive Summary
India-based drug makers, who have built themselves into regional powerhouses thanks to their efforts in creating small molecules generics, are keenly interested in the biosimilar opportunity. But none has been as aggressive-or as brash - as Dr. Reddy's Laboratories. (This is a sidebar to the article "Opening A Door To Biosimilars In the US."
You may also be interested in...
Opening A Door To Biosimilars In The US
With the regulatory door ajar, companies across the pharmaceutical industry are vying to dominate the biosimilars space, despite the commercial risks.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.